Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aethlon Medical, Inc. (Nasdaq: AEMD) SEC filings page on Stock Titan brings together the company’s U.S. regulatory documents, giving investors direct access to the disclosures that frame its clinical and financial profile. Aethlon is a clinical-stage medical device company based in San Diego, California, focused on developing the investigational Hemopurifier to address unmet needs in oncology and life-threatening infectious diseases.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Aethlon’s business, risk factors, Hemopurifier development programs, and financial condition. Current reports on Form 8-K provide detail on material events such as public offerings and private placements of common stock and warrants, reverse stock split actions, Nasdaq listing notices and compliance updates, and key clinical and corporate announcements referenced in company press releases.
For those tracking AEMD’s capital structure, registration statements on Form S-1 and related amendments outline the terms of securities offerings, including common stock, pre-funded warrants, and common stock purchase warrants, as well as associated registration rights. These filings explain how many shares and warrants are being registered, exercise prices and durations, and the company’s stated use of proceeds for working capital, clinical trial expenses, research and development, and other corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight key elements of lengthy documents, helping readers quickly identify items such as Hemopurifier development disclosures, Nasdaq listing discussions, and financing terms. Real-time updates from EDGAR ensure that new Aethlon Medical filings appear promptly, while dedicated sections make it easier to locate material 8-Ks, registration statements, and periodic reports relevant to AEMD’s evolving clinical-stage strategy.
Rossetti Angela reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical director Angela Rossetti received an equity award of 21,815 shares of Common Stock at $2.29 per share. The award is structured as RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, contingent on her continued service. Following this grant, she directly owns 26,207 shares.
Shah Chetan reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical director Chetan Shah received a stock-based compensation grant. He was awarded 21,815 shares of Common Stock at a reference price of $2.29 per share, classified as a grant or award, increasing his directly held stake to 23,021 shares.
The award represents RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company on each vesting date. This is a routine compensation-related equity grant rather than an open-market purchase.
BROENNIMAN EDWARD G reported acquisition or exercise transactions in this Form 4 filing.
Aethlon Medical Inc director Edward G. Broenniman reported an equity award of 21,815 shares of Common Stock at $2.29 per share. The award is in the form of RSUs that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, subject to his continued service with the company on each vesting date. Following this grant, he directly holds 23,454 shares of Aethlon Medical common stock.
Aethlon Medical Inc. director Nicolas Gikakis received a stock-based compensation award in the form of 21,815 shares of common stock on April 17, 2026. The award is structured as restricted stock units that vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, conditioned on his continued service with the company. Following this grant, he directly holds 22,844 shares of Aethlon Medical common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.
Aethlon Medical director Chetan Shah reported a tax-related share forfeiture tied to equity compensation. On conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares at $2.19 per share to cover tax withholdings, based on the market price at the time.
Following this non-market transaction, Shah directly holds 1,463 shares of Aethlon Medical common stock. The disposition reflects routine tax settlement rather than an open-market sale or purchase decision.
Aethlon Medical director Nicolas Gikakis reported a tax-related share forfeiture. On the conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares to cover tax withholdings, using a market price of $2.19 per share. Following the disposition, he holds 1,464 common shares directly.
Aethlon Medical director Edward G. Broenniman reported a routine tax-withholding disposition related to restricted stock units. He forfeited 89 shares of common stock, valued at $2.19 per share, to cover taxes upon conversion of 357 vested RSUs. After this transaction, he directly holds 1,915 shares.
Aethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. The company stated that all previously outstanding pre-funded warrants have now been exercised, simplifying its capital structure by converting those warrant rights into common shares.
Aethlon Medical, Inc. held its Annual Meeting on February 19, 2026, where stockholders approved several measures that significantly expand the company’s equity capacity. The Articles of Incorporation were amended to increase authorized common stock from 6,000,000 to 100,000,000 shares.
Stockholders also approved adding 100,000 shares to the 2020 Equity Incentive Plan and ratified Haskell & White LLP as auditor for the year ending March 31, 2026. For Nasdaq Listing Rule 5635(d) purposes, stockholders approved the potential issuance of up to 1,662,553 shares of common stock tied to various warrants under a Securities Purchase Agreement dated December 5, 2025, and up to 368,471 shares issuable upon exercise of additional warrants from a Warrant Inducement Agreement. The meeting had a quorum, with 556,359 of 973,213 outstanding shares represented.
AETHLON MEDICAL INC Schedule 13G reports beneficial ownership of 84,496 shares, equal to 9.99% of the common stock as of 12/31/2025.
The filing states Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., and that Armistice Capital and Steven Boyd may be deemed to beneficially own these shares through voting and dispositive power under an Investment Management Agreement.